News >

EU Panel Backs Pembrolizumab Plus Axitinib for Frontline RCC

Jason M. Broderick @jasoncology
Published: Monday, Jul 29, 2019

Scot Ebbinghaus, MD, vice president, clinical research, Merck Research Laboratories

Scot Ebbinghaus, MD

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of pembrolizumab (Keytruda) in combination with axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).

The FDA approved the pembrolizumab/axitinib combination in April 2019 for use in this setting.
Powles T, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib vs sunitinib as first-line therapy for advanced renal cell carcinoma: KEYNOTE-426. J Clin Oncol. 2019;37(suppl 15; abstr 543) doi: 10.1200/JCO.2019.37.7_suppl.543.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication